Lupin strengthens presence in South Africa with acquisition of nine brands from MNI

New Delhi: Lupin Limited has expanded its reach in the Complementary and Alternative Medicines (CAM) sector by acquiring nine key brands from the Medical Nutritional Institute (MNI) in South Africa. This strategic acquisition was facilitated by Lupin’s South African subsidiary, Pharma Dynamics, through a partnership with investment firm ImpiloVest.

The newly acquired brands—AntaGolin, RyChol, NeuroVance, SkinVance, FlamLeve, Rheumalin, SleepVance, ImmunoVance, and OviVance—address a wide array of health concerns such as metabolic syndrome, insulin resistance, cognitive function, skin health, inflammation, joint care, sleep quality, immune support, and hormonal well-being for women.

MNI is known for its focus on phytochemical, or plant-based, solutions that target metabolic syndrome. The acquisition allows Lupin to expand into the South African retail market with these established brands, strengthening its foothold in the growing CAM sector.

“This acquisition is a major step for Lupin to expand our footprint in the Complementary and Alternative Medicines sector. MNI’s innovative plant-based products align perfectly with our goal to provide holistic and sustainable healthcare solutions to our patients in South Africa,” said Thierry Volle, President EMEA at Lupin.

Erik Roos, CEO of Pharma Dynamics, highlighted, “There is a growing trend of patients seeking proactive healthcare solutions. This acquisition broadens our product range by concentrating on metabolic diseases such as cardiovascular disease, diabetes, and neuroscience, thereby enhancing patient health and well-being.”

Mariaan du Plessis, CEO of MNI, expressed, “We are proud to partner with a company that shares our dedication to holistic and preventive healthcare. MNI’s unique plant-based formulations, developed in 2002 by a team of healthcare professionals, have been extensively tested to ensure their efficacy.”